Multipurpose prevention technologies: The future of HIV and STI protection

Trends in Microbiology

Volumn 23, Issue 7, 2015, Pages 429-436

  Fernández Romero, José A ^a   Deal, Carolyn ^b   Herold, Betsy C ^c   Schiller, John ^d   Patton, Dorothy ^e   Zydowsky, Thomas ^a   Romano, Joe ^f   Petro, Christopher D ^c   Narasimhan, Manjulaa ^g  

^a POPULATION COUNCIL   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f NWJ Group LLC   (United States)

^g WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

HIV; HPV; HSV 2; Multipurpose prevention technologies; STI; Trichomonas vaginalis

Indexed keywords

ACICLOVIR; ANTIINFECTIVE AGENT; CARRAGEENAN; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; GRIFFITHSIN; IQP 0528; LEVONORGESTREL; METRONIDAZOLE; MICROBICIDE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MAPP66; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; POLY [1,4 PHENYLENE (1 CARBOXY) METHYLENE]; TENOFOVIR; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG;

BIOGEOGRAPHIC REGION; DISEASE ASSOCIATION; DISEASE TRANSMISSION; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; GEL; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HEALTH CARE ORGANIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION PREVENTION; MEDICAL RESEARCH; MEDICATION COMPLIANCE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH; REPRODUCTIVE HEALTH; REVIEW; SEXUALLY TRANSMITTED DISEASE; TREATMENT INDICATION; TRICHOMONIASIS; UNPLANNED PREGNANCY; CONTRACEPTION; FEMALE; HERPES GENITALIS; HIV INFECTIONS; PAPILLOMAVIRUS INFECTIONS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; SEXUALLY TRANSMITTED DISEASES; SOUTH AFRICA; TRANSMISSION; TRICHOMONAS VAGINITIS;

HUMAN HERPESVIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN PAPILLOMAVIRUS; TRICHOMONAS VAGINALIS;

CONTRACEPTION; FEMALE; HERPES GENITALIS; HIV INFECTIONS; HUMANS; PAPILLOMAVIRUS INFECTIONS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY, UNPLANNED; PREVALENCE; SEXUALLY TRANSMITTED DISEASES; SOUTH AFRICA; TRICHOMONAS VAGINITIS;

EID: 84937633540     PISSN: 0966842X     EISSN: 18784380     Source Type: Journal    
DOI: 10.1016/j.tim.2015.02.006     Document Type: Review

References (59)

1. Hayes R., et al. Treatment of sexually transmitted infections for HIV prevention: end of the road or new beginning?. Aids 2010, 24(Suppl. 4):S15-S26.
2. de Sanjose S., Palefsky J. Cervical and anal HPV infections in HIV positive women and men. Virus Res. 2002, 89:201-211.
3. Tan D.H., et al. Herpes simplex virus type 2 and HIV disease progression: a systematic review of observational studies. BMC Infect. Dis. 2013, 13:502.
4. Ghys P.D., et al. The associations between cervicovaginal HIV shedding, sexually transmitted diseases and immunosuppression in female sex workers in Abidjan, Cote d'Ivoire. Aids 1997, 11:F85-F93.
5. Fernandez-Romero J.A., et al. Preclinical assessments of vaginal microbicide candidate safety and efficacy. Adv. Drug Deliv. Rev. 2014, Published online December 24, 2014. http://dx.doi.org/10.1016/j.addr.2014.12.005.
6. Looker K.J., et al. An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. Bull. World Health Organ. 2008, 86:805-812.
7. Corey L., et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N. Engl. J. Med. 2004, 350:11-20.
8. Freeman E.E., et al. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. Aids 2006, 20:73-83.
9. Strick L.B., et al. Management of herpes simplex virus type 2 infection in HIV type 1-infected persons. Clin. Infect. Dis. 2006, 43:347-356.
10. Belshe R.B., et al. Efficacy results of a trial of a herpes simplex vaccine. N. Engl. J. Med. 2012, 366:34-43.
11. Abdool Karim Q., et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010, 329:1168-1174.
12. Celum C., et al. Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial. Ann. Intern. Med. 2014, 161:11-19.
13. Mesquita P.M., et al. Intravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infection. J. Antimicrob. Chemother. 2012, 67:1730-1738.
14. Nixon B., et al. Vaginally delivered tenofovir disoproxil fumarate provides greater protection than tenofovir against genital herpes in a murine model of efficacy and safety. Antimicrob. Agents Chemother. 2014, 58:1153-1160.
15. Mori T., et al. Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp. J. Biol. Chem. 2005, 280:9345-9353.
16. O'Keefe B.R., et al. Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:6099-6104.
17. Nixon B., et al. Griffithsin protects mice from genital herpes by preventing cell-to-cell spread. J. Virol. 2013, 87:6257-6269.
18. Patel S., et al. Seminal plasma reduces the effectiveness of topical polyanionic microbicides. J. Infect. Dis. 2007, 196:1394-1402.
19. Segarra T.J., et al. Bridging the gap between preclinical and clinical microbicide trials: blind evaluation of candidate gels in murine models of efficacy and safety. PLoS ONE 2011, 6:e27675.
20. Fernandez-Romero J.A., et al. Zinc acetate/carrageenan gels exhibit potent activity in vivo against high-dose herpes simplex virus 2 vaginal and rectal challenge. Antimicrob. Agents Chemother. 2012, 56:358-368.
21. Kenney J., et al. A modified zinc acetate gel, a potential nonantiretroviral microbicide, is safe and effective against simian-human immunodeficiency virus and herpes simplex virus 2 infection in vivo. Antimicrob. Agents Chemother. 2013, 57:4001-4009.
22. Kizima L., et al. A potent combination microbicide that targets SHIV-RT, HSV-2 and HPV. PLoS ONE 2014, 9:e94547.
23. Rodriguez A., et al. In vitro and in vivo evaluation of two carrageenan-based formulations to prevent HPV acquisition. Antiviral Res. 2014, 108:88-93.
24. Herold B.C., et al. Mandelic acid condensation polymer: novel candidate microbicide for prevention of human immunodeficiency virus and herpes simplex virus entry. J. Virol. 2002, 76:11236-11244.
25. Mesquita P.M., et al. Candidate microbicide PPCM blocks human immunodeficiency virus type 1 infection in cell and tissue cultures and prevents genital herpes in a murine model. J. Virol. 2008, 82:6576-6584.
26. Doorbar J., et al. The biology and life-cycle of human papillomaviruses. Vaccine 2012, 30(Suppl. 5):F55-F70.
27. Roberts J.N., et al. Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat. Med. 2007, 13:857-861.
28. Roberts J.N., et al. Effect of Pap smear collection and carrageenan on cervicovaginal human papillomavirus-16 infection in a rhesus macaque model. J. Natl. Cancer Inst. 2011, 103:737-743.
29. Johnson K.M., et al. Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus. J. Virol. 2009, 83:2067-2074.
30. Kines R.C., et al. The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:20458-20463.
31. Schiller J.T., et al. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012, 30(Suppl. 5):F123-F138.
32. Day P.M., et al. In vivo mechanisms of vaccine-induced protection against HPV infection. Cell Host Microbe 2010, 8:260-270.
33. Kirby T. FDA approves new upgraded Gardasil 9. Lancet Oncol. 2015, 16:e56.
34. Lowy D.R., Schiller J.T. Reducing HPV-associated cancer globally. Cancer Prev. Res. 2012, 5:18-23.
35. Auvert B., et al. Association of oncogenic and nononcogenic human papillomavirus with HIV incidence. J. Acquir. Immune Defic. Syndr. 2010, 53:111-116.
36. Lissouba P., et al. Association of genital human papillomavirus infection with HIV acquisition: a systematic review and meta-analysis. Sex. Transm. Infect. 2013, 89:350-356.
37. Buck C.B., et al. Carrageenan is a potent inhibitor of papillomavirus infection. PLoS Pathog. 2006, 2:e69.
38. Marais D., et al. The effectiveness of Carraguard, a vaginal microbicide, in protecting women against high-risk human papillomavirus infection. Antivir. Ther. 2011, 16:1219-1226.
39. Global Incidence and Prevalence of Selected Curable Sexually Transmitted Infections - 2008 2012, World Health Organization, WHO Department of Reproductive Health and Research.
40. Cosar C., Julou L. The activity of 1-(2-hydroxyethyl)-2-methyl-5-nitroimidazole (R.P. 8823) against experimental Trichomonas vaginalis infections. Ann. Inst. Pasteur. 1959, 96:238-241. (in French).
41. Kirkcaldy R.D., et al. Trichomonas vaginalis antimicrobial drug resistance in 6 US cities, STD Surveillance Network, 2009-2010. Emerg. Infect. Dis. 2012, 18:939-943.
42. Guffey M.B., et al. HPTN 035 phase II/IIb randomised safety and effectiveness study of the vaginal microbicides BufferGel and 0.5% PRO 2000 for the prevention of sexually transmitted infections in women. Sex. Transm. Infect. 2014, 90:363-369.
43. Kulda J. Employment of experimental animals in studies of Trichomonas vaginalis infections. Trichomonads Parasitic in Humans 1990, 112-154. Springer. B.M. Honigberg (Ed.).
44. Abraham M.C., et al. Inducible immunity to Trichomonas vaginalis in a mouse model of vaginal infection. Infect. Immun. 1996, 64:3571-3575.
45. Lushbaugh W.B., et al. Use of intravaginal microbicides to prevent acquisition of Trichomonas vaginalis infection in Lactobacillus-pretreated, estrogenized young mice. Am. J. Trop. Med. Hyg. 2000, 63:284-289.
46. Patton D.L., et al. Development of a nonhuman primate model for Trichomonas vaginalis infection. Sex. Transm. Dis. 2006, 33:743-746.
47. Harrison P.F., et al. Developing multipurpose reproductive health technologies: an integrated strategy. AIDS Res. Treat. 2013, 2013:790154.
48. Brady M., Tolley E. Aligning product development and user perspectives: social-behavioural dimensions of multipurpose prevention technologies. Bjog 2014, 121(Suppl. 5):70-78.
49. Landolt N.K., et al. Significant decrease of ethinylestradiol with nevirapine, and of etonogestrel with efavirenz in HIV-positive women. J. Acquir. Immune Defic. Syndr. 2014, 66:e50-e52.
50. Vieira C.S., et al. Effect of antiretroviral therapy including lopinavir/ritonavir or efavirenz on etonogestrel-releasing implant pharmacokinetics in HIV-positive women. J. Acquir. Immune Defic. Syndr. 2014, 66:378-385.
51. Perry S.H., et al. Implementing the Jadelle implant for women living with HIV in a resource-limited setting: concerns for drug interactions leading to unintended pregnancies. Aids 2014, 28:791-793.
52. Heffron R., et al. Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect. Dis. 2012, 12:19-26.
53. Marrazzo J.M., et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N. Engl. J. Med. 2015, 372:509-518.
54. Van Damme L., et al. Preexposure prophylaxis for HIV infection among African women. N. Engl. J. Med. 2012, 367:411-422.
55. van der Straten A., et al. Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: the VOICE-C qualitative study in Johannesburg, South Africa. J. Int. AIDS Soc. 2014, 17:19146.
56. Baeten J.M., et al. Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial. Lancet Infect. Dis. 2014, 14:1055-1064.
57. Baeten J.M., et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N. Engl. J. Med. 2012, 367:399-410.
58. Young Holt B., et al. Ensuring successful development and introduction of multipurpose prevention technologies through an innovative partnership approach. BJOG 2014, 121(Suppl. 5):3-8.
59. Manning J., et al. Challenges and opportunities in funding the development and introduction of multipurpose prevention technologies. BJOG 2014, 121(Suppl. 5):12-14.